Human TRAIL/TNFSF10 ELISA Kit
Key features and details
- Specification:
- Sensitivity:
- Standard Curve Range:
- Standard Curve Gradient:
- Number of Incubations:
- Sample Volume:
- Assay type:
- Operation Duration:
-
Brand:
CAT.NO. : AEH0176
RMB Please choose
RMB Please choose
Size:
Trail, Bulk size or Custom requests Please contact us
Product Details
Background
TRAIL (TNF-related apoptosis-inducing ligand), also known as APO-2 ligand, is a type II transmembrane protein with a carboxy-terminal extracellular domain which exhibits homology to other TNF family members. In the new TNF superfamily nomenclature, TRAIL is referred to as TNFSF10. Human TRAIL cDNA encodes a 281 amino acid (aa) residue protein with an amino-terminal intracellular domain of 17 residues and a predicted internal hydrophobic domain between residues 18 and 38. The extracellular carboxy-terminal domain contains a potential N-linked glycosylation site at amino acid residue 109. Among TNF family members, TRAIL is most homologous to FAS ligand, sharing 28% amino acid sequence identity in their extracellular domains. Mouse TRAIL has also been cloned. The human TRAIL shares 65% amino acid sequence identity with mouse TRAIL and is active on mouse cells. Both membrane bound and soluble TRAIL have been shown to induce rapid apoptosis of many transformed cell lines. Like most TNF family members, the bioactive TRAIL exists as a homotrimer. TRAIL transcripts have been shown to be constitutively expressed in a variety of human tissues. A family of TRAIL receptors, including two receptors that tranduce the apoptotic signals and two TRAIL decoy receptors that function to antagonize TRAIL-induced apoptosis, have been identified. Osteoprotegerin has been identified as a fifth TRAIL receptor.
Typical data
|
pg/ml |
O.D. |
Average |
Corrected |
|
|
0.00 |
0.0079 |
0.0090 |
0.0085 |
|
|
8.19 |
0.0236 |
0.0233 |
0.0235 |
0.0150 |
|
20.48 |
0.0491 |
0.0480 |
0.0486 |
0.0401 |
|
51.20 |
0.1139 |
0.1073 |
0.1106 |
0.1022 |
|
128.00 |
0.2820 |
0.2697 |
0.2759 |
0.2674 |
|
320.00 |
0.6811 |
0.6529 |
0.6670 |
0.6586 |
|
800.00 |
1.4760 |
1.4190 |
1.4475 |
1.4391 |
|
2000.00 |
2.7240 |
2.6890 |
2.7065 |
2.6981 |
Precision
|
Intra-assay Precision |
Inter-assay Precision |
|||||
|
Sample Number |
S1 |
S2 |
S3 |
S1 |
S2 |
S3 |
|
22 |
22 |
22 |
6 |
6 |
6 |
|
|
Average(pg/ml) |
76.8 |
298.2 |
834.6 |
72.7 |
285.1 |
730.8 |
|
Standard Deviation |
3.5 |
9.6 |
26.2 |
3.1 |
8.3 |
24.7 |
|
Coefficient of Variation(%) |
4.5 |
3.2 |
3.1 |
4.3 |
2.9 |
3.4 |
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human TRAIL/TNFSF10 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 80% to 120% with an overall mean recovery of 109%.
The recovery ranged from 80% to 120% with an overall mean recovery of 109%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 3.12-119.35 | 100 | 64.97 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of TRAIL/TNFSF10 in this assay. No medical histories were available for the donors.
New Products
